GREENFIELD — Elanco, the Greenfield-based animal health products company, is eliminating about 350 jobs at its facilities around the world. 50 of those positions are at its global headquarters in Hancock County.
The cutbacks are designed to "improve operational efficiency," the company said in a statement issued Tuesday, and follow Elanco's acquisition of Bayer Animal Health in 2020.
Elanco intends to close research and development sites in New Zealand and Germany. Changes will also be made in marketing, manufacturing, administration and quality central functions.
“With a number of milestones achieved since IPO, including the Bayer acquisition, today’s actions are the next step in our commitment to drive operational efficiencies and deliver attractive returns,” said Jeff Simmons, Elanco president and CEO. “As we start 2021, our team is clear on their priorities and brings momentum as we continue to execute and deliver against our expanded and strengthened IPP strategy.”
Through research and development, Elanco produces animal health products to prevent and treat diseases in farm animals and pets.
PREVIOUS: Elanco Animal Health to build global headquarters in downtown Indianapolis
The restructuring is not the only change Elanco is going through. In December, the company announced plans to move its headquarters, where about 900 people work, from Greenfield to a former General Motors industrial site just across the White River from downtown Indianapolis.
That move is a few years down the road.
